{"id":15973,"date":"2022-07-04T09:34:11","date_gmt":"2022-07-04T09:34:11","guid":{"rendered":"https:\/\/interhospi.com\/?p=15973"},"modified":"2023-09-06T08:28:34","modified_gmt":"2023-09-06T08:28:34","slug":"new-biomarker-predicts-severity-of-cardiac-remodelling-after-heart-attack","status":"publish","type":"post","link":"https:\/\/interhospi.com\/new-biomarker-predicts-severity-of-cardiac-remodelling-after-heart-attack\/","title":{"rendered":"New biomarker predicts severity of cardiac remodelling after heart attack"},"content":{"rendered":"
\n

<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

New biomarker predicts severity of cardiac remodelling after heart attack<\/h1>biomarker<\/a><\/span>, Cardiology<\/a><\/span>, heart attack<\/a><\/span>, Featured Articles<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

The Society of Nuclear Medicine and Molecular Imaging held this year\u2019s Annual Meeting in Vancouver, Canada from June 11-14. International Hospital looks at some of the research presented at the event.<\/strong><\/p>\n

<\/p>\n

Poor functional outcomes after a heart attack can be predicted with a new PET imaging agent, 68Ga-FAPI-46. According to research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting, when correlated with cardiac MRI, 68Ga-FAPI-46 PET is a new specific indicator of active fibrosis and can identify a patient\u2019s chances of recovery. The detailed depiction of 68Ga-FAPI-46 PET signal after acute anterior myocardial infarction has been selected as SNMMI\u2019s 2022 Image of the Year.<\/p>\n

Each year, SNMMI chooses an image that best exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence, and providing a means of selecting appropriate treatments. This year, the SNMMI Henry N. Wagner, Jr., Image of the Year was chosen from more than 1,000 abstracts submitted to the meeting and voted on by reviewers and the society leadership.<\/p>\n

Acute myocardial infarction, commonly known as heart attack, is one of the leading causes of death worldwide. After a heart attack, the heart goes through a series of changes at the molecular and cellular level. The fibroblast activation protein (FAP) is overexpressed as these changes occur and can provide useful information about a patient\u2019s prognosis.<\/p>\n

\u201cMolecular PET imaging of the fibroblast activation protein has recently been evaluated in patients after acute myocardial infarction,\u201d said Johanna Diekmann, MD, clinician scientist in the Department of Nuclear Medicine at the Hannover School of Medicine in Hannover, Germany. \u201cIn our study, we sought to obtain further insights by correlating FAP-targeted PET imaging with tissue characteristics from cardiac MRI, as well as functional outcome.\u201d<\/p>\n

Thirty-five patients underwent 68Ga-FAPI-46 PET\/CT, perfusion SPECT, and cardiac MRI within 11 days after a heart attack. Cardiac FAP-volume was determined by PET imaging and infarct size defined by SPECT imaging. Cardiac MRI showed functional parameters, area of injury and tissue mapping. These datapoints were then compiled to examine potential correlations.<\/p>\n

In all patients the FAP-upregulation was significantly larger than both the infarct size and the area of injury as defined by SPECT and cardiac MRI, respectively. A higher extent of myocardial FAP upregulation was predictive of subsequent left ventricular dysfunction. As such, the authors concluded, fibroblast activation in non-infarcted areas of the heart may contribute to adverse outcomes.<\/p>\n

\u201cMyocardial infarction is an important contributor to the development of heart failure, but the early molecular processes involved in the transition from initial injury to heart failure are under-treated,\u201d said Diekmann. \u201cNew antifibrotic therapies (such as CAR-T cell therapies) could significantly change future therapy of heart failure. Using FAPI-PET to select patients suitable for therapy would open a new major application for PET in fibrosis and cardiac diseases.\u201d<\/p>\n

\u201cFAPI is a very exciting radiotracer that holds great potential for the future of nuclear medicine and molecular imaging,\u201d noted Heather Jacene, MD, SNMMI Scientific Program chair. \u201cAs shown in the Image of the Year, 68Ga-FAPI-46 PET\/CT clearly indicates pro-fibrotic activity after acute myocardial infarction. The predictive value of FAPI-PET for the magnitude of subsequent decline in global cardiac function, if further validated, may be used in the future to help select the most suitable patients for anti-fibrotic therapies which are currently under development. This could ultimately have a powerful impact on cardiovascular medicine.\u201d<\/p>\n<\/div><\/section>
\n

<\/span><\/span><\/div>
\n
<\/div><\/div><\/div>
\n
<\/span><\/span><\/div>
\n